Company intelligence / Profile preview

Sichuan Xingtai Pule Medical Technology

Ownership: Private
Development stage: Other

Overview

The company's cardiovascular products have experienced long-term large-scale clinical application in real-world settings with broad affirmation from clinicians and patients. It has developed several “Chinese firsts” including carrier-free coronary drug stent, dual-chamber pacemaker, coronary bioabsorbable stent, cutting balloon, biodegradable occluder. It was also first in China to apply AI technology to ECG monitoring.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologicSmall molecule
Industry: Therapeutic Medical Devices

Partnerships

Global distributors and academic collaborations via parent company networkOver 20 global OEM partners through parent group.

Beyond the preview

Go deeper on Sichuan Xingtai Pule Medical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sichuan Xingtai Pule Medical Technology.

Explore the full profile